Infinity PHARMACEUTICALS

784 Memorial Drive
Cambridge, MA 02139
Tel: +1-617-453-1000
Fax:+1-617-453-1001

29 November 2016

RE: Change in Sponsor
Study IPI-145-19 (EudraCT Number 2014-005459-13)

Dear Sirs/Madams:

This letter is provided as notification of a change in Sponsor for Study IPI-145-19, "A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma".

Infinity Pharmaceuticals, Inc., located at 784 Memorial Drive, Cambridge, MA, 02139, USA, the current Sponsor of the referenced study, is transferring sponsorship of Study IPI-145-19 effective 01 January 2017 to:

Verastem, Inc. (Verastem)
117 Kendrick Street, Suite 500
Needham, MA 02494
USA

On the effective date, Verastem, Inc. will assume all sponsor responsibilities. A copy of all files relevant to this Clinical Trial Application have been provided to Verastem.

A Clinical Trial Application Form containing the required information for Sponsor Identification and Contact Person is provided with this submission. Please note that the Legal Representative for the Sponsor in the European Union, Pharm Olam International (Polska) Sp. z o.o, has not changed, as documented in the attached Clinical Trial Application. A Letter of Authorization listing the Sponsor Responsibilities delegated by Verastem, Inc. to Pharm Olam International, LLC and its subsidiaries and worldwide affiliates is attached.

Clinical Study IPI-145-19 is being terminated. In October 2016 investigators were notified of this early termination and informed that active patients could continue on treatment for an additional 3 months. It is expected that the date of the last patient's last visit will be in early January 2017, with follow-up visits occurring in February 2017.

Because this study is terminating in early 2017, clinical trial documents, such as the clinical protocol, informed consent form, Investigator's Brochure and clinical trial product labeling will not be updated with the new Sponsor information. All study participants will be notified of the change in sponsor by the study investigator during the next study visit and this will be documented within the investigator site file.

784 Memorial Drive
Cambridge, MA 02139
Tel: +1-617-453-1000
Fax:+1-617-453-1001

Investigators participating in this study are being notified of the planned Change in Sponsor.

If you have any questions or require additional information regarding this information, please contact me at, +1-617-453-1162 or tamyra.toole@infi.com.

Sincerely,

Tamyra A. Toole
Vice President
Regulatory Affairs and Quality Assurance